Efficacy and safety of Dalfaz in patients with symptoms of benign prostatic hyperplasia (seven years of observation)
The results of the study the effectiveness of long-term treatment with ?-adrenoblocker Dalfaz (alfuzosin), which included 41 patients of benign prostatic hyperplasia (BPH), are presented. The study demonstrated the high safety of Dalfaz administration in patients with urination disorders. Dalfaz has received a good mark as a safe and high effective drug for prolonged drug therapy for BPH. The study confirmed the principal possibility of permanent Dalfaz administration in patients with benign prostatic hyperplasia for many years as first-line drugs for medication correction of urination disorders in patients with BPH.

Keywords: Dalfaz, alfuzosin, alfa-blockers, lower urinary tract symptoms, benign prostatic hyperplasia